pharmaphorum| News & views on pharma and biotech’s evolving future

News

Despite study bust, Vistagen still hopes to file anxiety dru...

Vistagen has chalked up another trial failure for fasedienol, its drug candidate for social anxiety disorder.

R&D

Changing Faces: Pharma and biotech hires, May 2026

Looking back to May, the pharma and biotech sector saw a steady stream of senior leadership changes.

Market Access

Patient pathway activation and industry’s role in enabling a...

R&D

pharmaphorum podcast Episode 266, Parexel - Paul Bridges and Charlotte Moser

Parexel: Flawless execution, policy shifts & patient-centric...

Parexel's Paul Bridges & Charlotte Moser discuss Europe's biotech sector in the face of an innovation cliff.

News

Drugmakers asked to defend Chinese trials; reports

The House China Select Committee has quizzed MSD, AbbVie, Bristol Myers Squibb, and Pfizer about the ethics of clinical trials run in China.

Featured Content

R&D

Changing Faces: Pharma and biotech hires, May 2026

Looking back to May, the pharma and biotech sector saw a steady stream of senior leadership changes.

Market Access

Patient pathway activation and industry’s role in enabling a...

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

R&D

Parexel: Flawless execution, policy shifts & patient-centric...

Parexel's Paul Bridges & Charlotte Moser discuss Europe's biotech sector in the face of an innovation cliff.

Oncology

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

At ASCO 26, Daiichi Sankyo leaders Ken Keller and John Tsai chatted with pharmaphorum about their big year of oncology launches, halfway in.

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

Newsletters and Deep Dive
digital magazine

Latest News

News

Despite study bust, Vistagen still hopes to file anxiety dru...

Vistagen has chalked up another trial failure for fasedienol, its drug candidate for social anxiety disorder.

News

Drugmakers asked to defend Chinese trials; reports

The House China Select Committee has quizzed MSD, AbbVie, Bristol Myers Squibb, and Pfizer about the ethics of clinical trials run in China.

News

Unicycive hits another hurdle with hyperphosphataemia drug

Unicycive Therapeutics' hopes of getting FDA approval of its drug for hyperphosphataemia in dialysis patients have been knocked back again.

News

Brukinsa data raises chemo-free hope for mantle cell lymphom...

Patients with newly diagnosed mantle cell lymphoma could avoid chemotherapy with a regimen based on BeOne's Brukinsa, according to the MANGROVE trial.

Views & Analysis

R&D

Changing Faces: Pharma and biotech hires, May 2026

Looking back to May, the pharma and biotech sector saw a steady stream of senior leadership changes.

R&D

Parexel: Flawless execution, policy shifts & patient-centric...

Parexel's Paul Bridges & Charlotte Moser discuss Europe's biotech sector in the face of an innovation cliff.

Sales & Marketing

Pharmacist reads doctor's notes with AI overlay concept in pharmacy

How pharma can make pharmacies a powerful marketing channel

Among POC marketing strategies, activating the pharmacy environment is especially powerful.

Oncology

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

At ASCO 26, Daiichi Sankyo leaders Ken Keller and John Tsai chatted with pharmaphorum about their big year of oncology launches, halfway in.

Deep Dive

Market Access

Market Access 2026

Market Access

Five dynasties that built modern pharma

Market Access

MFN and TrumpRx: What’s the real impact for the American con...

Market Access

The expanding role of early-phase trials in modern drug deve...

White Papers & Webinar

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

Digital

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

Podcasts & Video

R&D

Parexel: Flawless execution, policy shifts & patient-centric...

Parexel's Paul Bridges & Charlotte Moser discuss Europe's biotech sector in the face of an innovation cliff.

Oncology

ASCO 2026: Three ADC approvals in five days, with Ken Keller...

At ASCO 26, Daiichi Sankyo leaders Ken Keller and John Tsai chatted with pharmaphorum about their big year of oncology launches, halfway in.

Oncology

ASCO 2026: Can a blood test spot cancer early? with Dr Peter...

Dr Peter Sasieni, co-investigator for the NHS Galleri trial, discusses advances in population-level blood screening for early cancer detection.

Oncology

pharmaphorum podcast Episode 265, Leonard Mazur, Citius

6th Rare & Genetic Kidney Disease Drug Development Summit

The 6th Rare & Genetic Kidney Disease Drug Development Summit returns to Boston on August 18–20, 2026, bringing together global leaders advanc

Featured Content

Editor's Picks

Latest News

Views & Analysis

Deep Dive

White Papers & Webinar

Podcasts & Video

Partner Content